GlassScriptPhysician profile
David Guel
NPI 1457782559
$8,848.54
in general payments reported to CMS, 2019-2025
22 companies · $510 in 2025
The $510 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,861 · 2020: $2,419 · 2021: $126 · 2022: $2,374 · 2023: $504 · 2024: $53.75 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $4,076.57 | 2019-2025 | Mitris Resilia Mitral Valve, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Intuitive Surgical, INC. | $1,520.50 | 2020 | |
| Abbott Laboratories | $1,443.50 | 2019-2025 | Navitor, Epic |
| Atricure, INC. | $455.39 | 2019-2025 | Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System, Atriclip Laa Exclusion System |
| Abiomed | $409.25 | 2022-2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $233.68 | 2021-2025 | Lifevest |
| Medtronic, INC. | $185.90 | 2022 | |
| Glaxosmithkline, LLC. | $120.65 | 2019 | |
| Cardiva Medical, INC. | $72.67 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Janssen Pharmaceuticals, INC | $70.29 | 2022 | |
| Boston Scientific Corporation | $49.50 | 2019 | |
| Artivion, INC. | $41.85 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $26.56 | 2021 | |
| Terumo Medical Corporation | $20.19 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.10 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kls-Martin L.P. | $16.60 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.33 | 2022 | |
| Merck Sharp & Dohme LLC | $16.27 | 2022 | |
| Chiesi USA, INC. | $14.66 | 2020 | |
| Getinge USA Sales, LLC | $13.75 | 2024 | Heartstring III Proximal Seal |
| Medtronic Vascular, INC. | $13.60 | 2020 | |
| Pfizer INC. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Guel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.